120 related articles for article (PubMed ID: 11284622)
1. Advances in the treatment of non-small cell lung cancer: molecular markers take the stage.
Rosell R; Green M; Gumerlock P
Semin Oncol; 2001 Feb; 28(1 Suppl 2):28-34. PubMed ID: 11284622
[TBL] [Abstract][Full Text] [Related]
2. Advances in the treatment of non-small cell lung cancer: Molecular markers take the stage.
Rosell R; Green M; Gumerlock P
Semin Oncol; 2001 Feb; 28 Suppl 2():28-34. PubMed ID: 28140079
[TBL] [Abstract][Full Text] [Related]
3. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Harper P
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer.
Hainsworth JD; Vokes EE
Semin Oncol; 2001 Feb; 28(1 Suppl 2):22-7. PubMed ID: 11284621
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
Stupp R; Mayer M; Kann R; Weder W; Zouhair A; Betticher DC; Roth AD; Stahel RA; Majno SB; Peters S; Jost L; Furrer M; Thierstein S; Schmid RA; Hsu-Schmitz SF; Mirimanoff RO; Ris HB; Pless M
Lancet Oncol; 2009 Aug; 10(8):785-93. PubMed ID: 19604722
[TBL] [Abstract][Full Text] [Related]
7. New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations.
Rosell R
Semin Oncol; 1999 Jun; 26(3 Suppl 11):32-7. PubMed ID: 10458209
[TBL] [Abstract][Full Text] [Related]
8. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.
Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S
Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant therapy for non-small cell lung cancer.
Gandara DR; Lara PN; Goldberg Z; Roberts P; Lau DH
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S5-9. PubMed ID: 11340902
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer.
Mattson K
Semin Oncol; 1999 Jun; 26(3 Suppl 10):25-8. PubMed ID: 10437748
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
Wozniak AJ; Gadgeel SM
Oncology (Williston Park); 2007 Feb; 21(2):163-71; discussion 171, 174, 179-82. PubMed ID: 17396481
[TBL] [Abstract][Full Text] [Related]
13. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
14. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G
Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Miller VA; Kris MG
Semin Oncol; 2000 Apr; 27(2 Suppl 3):3-10. PubMed ID: 10810932
[TBL] [Abstract][Full Text] [Related]
18. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions.
Bunn PA
Semin Oncol; 1994 Jun; 21(3 Suppl 6):49-59. PubMed ID: 8052874
[TBL] [Abstract][Full Text] [Related]
19. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments.
Belani CP
Semin Oncol; 1999 Jun; 26(3 Suppl 10):15-8. PubMed ID: 10437746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
